There really is no such thing as mild diabetes: a new perspective on an old idea


  • Mike Baxter Sanofi, Guildford, UK
  • Richard Hudson Sanofi, Guildford, UK



Improved outcomes, Population based strategy, Sustained small improvements benefits, Apparent clinical inertia, Low risk is not no risk, Prevention of progression


Textbook of diabetes. Blackwell Scientific Publications, 1991.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.

Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818-28.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.

Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855-62.

Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373-8.

Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44.

McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24.

Hornberger J. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood Challenge Meeting. Value Health 2013;16:453-4.

Palmer AJ, Roze S, Valentine WJ, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004; 20(Suppl 1):S53–S58.

Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. Int J Clin Pract 2006;60:1138-45.

Baxter M, Hudson R, Mahon J, et al. Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications, and the associated financial benefit. Diabet Med 2016;33:1575-81.

Mencken HL. A Mencken Chrestomathy. 1949.

Department of Health. National Service Framework for diabetes: delivery strategy. 2002 (accessed 18 March 2016).

Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

National Audit Office. The management of adult diabetes services in the NHS. 2012 (accessed 18 March 2016).

National Audit Office. The management of adult diabetes services in the NHS: progress review. 2015 (accessed 18 March 2016).

Diabetes UK. State of the Nation 2016 (accessed 19 July 2016).

Ambrose ML, Kulik C. Old friends, new faces: motivation research in the 1990s. J Management 1999;25:231-92.

Lopes LL. Between hope and fear: the psychology of risk. Advan Exp Social Psychol 1987;20:255-95.

Deming E. Out of the crisis. MIT Technology Centre for Advanced Engineering Study, Cambridge, MA, 1990.

Gregory AJ. Target setting, lean systems and viable systems: a systems perspective on control and performance measurement. J Operational Res Soc 2007;58:1503-17.

Khunti K, Anderson M, Wolden ML, Davies ML, Thorsted BL. Clinical inertia in people with type 2 diabetes. A retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-17.

CSD Patient Data CSDUL. Derived from the CSD database. 2014.

Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788-95.

Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target- versus risk-based blood pressure treatment. Circulation 2016;133:840-8.